|
04 Nov 2023 |
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
|
|
04 Nov 2023 |
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
|
|
04 Nov 2023 |
Ankyra Therapeutics Announces Promising Preclinical Data on ANK-101, a Novel Anchored Immune Medicine, in Combination with Cytotoxic Chemotherapy in Head and Neck Cancer Model
|
|
04 Nov 2023 |
Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial
|
|
04 Nov 2023 |
InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial
|
|
04 Nov 2023 |
Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability
|
|
03 Nov 2023 |
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
|
|
03 Nov 2023 |
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
|
|
03 Nov 2023 |
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
|
|
03 Nov 2023 |
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
|
|
03 Nov 2023 |
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
|
|
03 Nov 2023 |
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
|
|
03 Nov 2023 |
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
|
|
03 Nov 2023 |
Actym to Present Preclinical Data on Clinical Candidate ACTM-838 at 38th SITC Annual Meeting
|
|
03 Nov 2023 |
HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting
|
|
03 Nov 2023 |
Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma
|
|
03 Nov 2023 |
Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350, a Potential Pan-Cancer Therapeutic
|
|
03 Nov 2023 |
Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window
|
|
03 Nov 2023 |
ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endometrial Cancers, at SITC 2023
|
|
03 Nov 2023 |
OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting
|
